Fractionated plasma separation and adsorption system: A novel system for blood purification to remove albumin bound substances

被引:164
作者
Falkenhagen, D
Strobl, W
Vogt, G
Schrefl, A
Linsberger, I
Gerner, FJ
Schoenhofen, M
机构
[1] Danube Univ Krems, Ctr Biomed Technol, A-3500 Krems, Austria
[2] Fresenius Med Care Gmbh, St Wendel, Germany
关键词
blood purification; membrane technology; adsorption; albumin bound substances; liver support system;
D O I
10.1046/j.1525-1594.1999.06292.x
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The removal of albumin bound substances has gained increasing interest in different diseases, especially in acute and chronic liver disease. Therefore, a new system, the fractionated plasma separation and adsorption (FPSA) system, was developed based on combined membrane and adsorbent blood purification techniques. The most important contribution to the FPSA system was the development of a new polysulfone hollow-fiber filter, which is characterized by a sieving coefficient of 0.89 for human serum albumin (HSA) but only of 0.17 for fibrinogen, and 0 (zero) for IgM immunoglobulins. Using a closed filtrate circuit connected to the new polysulfone filter which integrates 1 or 2 adsorption columns and also a high flux dialyzer adapted to a dialysis machine, the FPSA system opens excellent possibilities for the relatively specific removal of albumin bound substances from the blood such as albumin bound bilirubin or even tryptophan. In comparison to other systems (for example, the Molecular Adsorbent Recirculating System [MARS] and albumin dialysis systems), the FPSA system enables much higher elimination of strongly bound albumin substances. The first clinical investigations have recently started based on a modified dialysis machine designed with all necessary safety measures.
引用
收藏
页码:81 / 86
页数:6
相关论文
共 26 条
[1]  
Akizawa T, 1998, Ther Apher, V2, P1, DOI 10.1111/j.1744-9987.1998.tb00065.x
[2]   PLASMAPHORESIS, CHARCOAL, AND RESIN PERFUSION IN EXPERIMENTAL PORCINE HEPATIC-FAILURE [J].
ALP, MH ;
HICKMAN, R .
DIGESTIVE DISEASES AND SCIENCES, 1986, 31 (02) :181-187
[3]  
ASH SR, 1992, INT J ARTIF ORGANS, V15, P151
[4]  
ASH SR, 1998, ASAIO J, V44, pA92
[5]   Current status in extracorporeal immunomodulation: Immune disorders [J].
Bosch, T .
ARTIFICIAL ORGANS, 1996, 20 (08) :902-905
[6]  
CUTLER RE, 1987, ANNU REV PHARMACOL, V27, P169
[7]   EXPERIMENTAL BILIRUBIN ENCEPHALOPATHY . MODE OF ENTRY OF BILIRUBIN-14C INTO CENTRAL NERVOUS SYSTEM [J].
DIAMOND, I ;
SCHMID, R .
JOURNAL OF CLINICAL INVESTIGATION, 1966, 45 (05) :678-&
[8]  
Falkenhagen D, 1990, Contrib Nephrol, V78, P142
[9]  
FALKENHAGEN D, 1994, BIOMED TECH, V39, P105
[10]  
FALKENHAGEN D, 1994, Patent No. 04559